NJ S3904

New Jersey state agencies would be prohibited from purchasing opioid antidotes (including naloxone/Narcan) from pharmaceutical manufacturers or distributors that have settled legal claims with any state government over actions contributing to the opioid epidemic

Companies that settled opioid-related lawsuits, including their affiliates and subsidiaries, would be barred from responding to state procurement requests or selling opioid overdose medications to the state

The prohibition applies to the Division of Purchase and Property in the Department of the Treasury and all executive, legislative, and judicial branch agencies with purchasing authority

Existing settlement obligations requiring companies to provide opioid antidotes to New Jersey under agreements entered before September 1, 2024 would continue until fulfilled

The restriction covers all FDA-approved opioid overdose treatments, regardless of dosage or administration method